Covid-19: Pfizer/BioNTech vaccine judged safe for use in UK - BBC News
Comparison between one and two dose SARS-CoV-2 vaccine prioritization for a fixed number of vaccine doses | Journal of The Royal Society Interface
Those Who Had COVID-19 May Only Need One Dose of Vaccine | Penn Medicine
Evaluation of COVID-19 vaccination strategies with a delayed second dose | medRxiv
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months | NEJM
Are coronavirus vaccines effective against variants? | NHK WORLD-JAPAN News
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet
Danish study on the efficacy of Pfizer/BioNTech SARS-CoV-2 vaccine after first and second dose
Covid vaccines slash risk of infection, illness and death, UK studies find | Financial Times
Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study - The Lancet Respiratory Medicine
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar | Nature Medicine
Evaluation of COVID-19 vaccination strategies with a delayed second dose | PLOS Biology
Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021 | MMWR
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study | The BMJ
Pfizer-BioNTech COVID-19 vaccine shows real-world efficacy, despite the circulation of B.1.1.7 variant
Evaluation of COVID-19 vaccination strategies with a delayed second dose | medRxiv
Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina | NEJM
Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults | Nature
Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study | The BMJ
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine | NEJM
Rollout Strategy for the Pfizer-BioNTech COVID-19 Vaccine in Ontario - Ontario COVID-19 Science Advisory Table
Evaluation of COVID-19 vaccination strategies with a delayed second dose | PLOS Biology
Pfizer vaccine may offer strong protection after first dose, Israeli study finds
Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study | The BMJ
Care needed' after getting Covid vaccine - BBC News
